State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 7,737,938 shares of Compass Therapeutics Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 7,737,938 shares of Compass Therapeutics Inc common stock.
  • Percent of class: The reported stake represents 4.3% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared voting power over 7,587,678 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over 7,737,938 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The shares are attributed to subsidiaries SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser.
  • Triggering event date: The event requiring the filing occurred on September 30, 2026.

State Street Corporation Discloses Passive Stake in Compass Therapeutics

According to the Schedule 13G filed November 10, 2026, State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, reported beneficial ownership of 7,737,938 shares of common stock in Compass Therapeutics Inc (CUSIP: 20454B104). Compass Therapeutics is headquartered at 80 Guest St Suite 601, Brighton, Massachusetts 02135, according to the filing.

The filing identifies State Street as a parent holding company ("HC" type reporting person) and indicates the position is held through three subsidiary investment advisers: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; and State Street Global Advisors Trust Company. State Street reported zero sole voting power and zero sole dispositive power over the shares, with shared voting power covering 7,587,678 shares and shared dispositive power covering the full 7,737,938 shares reported.

The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026. Item 5 of the filing notes ownership of 5 percent or less of the class. The certification included states that, to the best of the filer's knowledge, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 4.3% beneficial ownership position in Compass Therapeutics Inc common stock, totaling 7,737,938 shares as of September 30, 2026, held through three investment adviser subsidiaries with shared but no sole voting or dispositive power.